HLA-C and neoplasm: On the one hand, epigenetic modulating agents may coordinately promote tumor immunogenicity by inducing de novo expression of transcriptionally repressed tumor-associated antigens, increasing expression of neoantigens and major histocompatibility complex (MHC) processing/presentation machinery, and activating tumor immunogenic cell death [8].